ClinicalTrials.gg
Sign In
RecruitingNCT07354438AD-MetS-DAIUpdated Jan 21, 2026

Assessing the Effect of an Antioxidant-Rich Diet on Metabolic Syndrome Risk Using the Dietary Antioxidant Index

An interventional study of Antioxidant-Focused Diet Intervention in Metabolic Syndrome Risk Factors, sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Metabolic syndrome (MetS) is a cluster of metabolic disorders characterized by elevated levels of blood glucose, hypertension, dyslipidemia, and abdominal obesity. Globally, it is a major public health concern. International studies have linked higher Dietary Antioxidant Index with reduced risk of MetS, as antioxidants play a role in lowering the risk of MetS by reducing oxidative stress, a key contributor to its pathophysiology. Exploring this link in Pakistan can provide valuable insights for dietary strategies to reduce the risk of MetS.

Read the detailed description

Background: Metabolic syndrome (MetS) is a cluster of metabolic disorders characterized by elevated levels of blood glucose, hypertension, dyslipidemia, and abdominal obesity. Globally, it is a major public health concern. International studies have linked higher Dietary Antioxidant Index (DAI) scores with reduced risk of MetS, as antioxidants play a role in lowering the risk of MetS by reducing oxidative stress, a key contributor to its pathophysiology. Exploring this link in Pakistan can provide valuable insights for dietary strategies to reduce the risk of MetS.

Hypothesis: A dietary intervention aimed at improving Dietary Antioxidant Index (DAI) scores beneficially affects Metabolic Syndrome risk factors among urban adults at risk of developing Metabolic Syndrome.

Material and Methods: A single-group pre-post human interventional study will be conducted among at-risk urban adults identified through the NCEP ATP III and WHO criteria. Dietary recalls will be analyzed in NutriSurvey using the Pakistan Food Composition Table, and any missing nutrient values will be supplemented from the Indian Food Composition Table. Nutrient data will be used to calculate the Dietary Antioxidant Index (DAI). Individuals with low DAI will receive dietary intervention.

Statistical Analysis: Pre-post changes in DAI and MetS markers will be assessed using paired t-tests, and Pearson's correlation will determine their associations using SPSS 25.

Expected Outcomes: The intervention is expected to reduce key Metabolic Syndrome risk factors while increasing individuals' awareness and motivation to adopt healthier behaviors.

02

Conditions studied

  • Metabolic Syndrome Risk Factors

Browse trials for

Keywords

  • Antioxidants
  • Dietary antioxidant index
  • Metabolic Syndrome risk
03

In context

Metabolic Syndrome

2,116 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.

This study's planned enrollment of 55 is close to the median of 60 across 1,572 interventional studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

University of Veterinary and Animal Sciences, Lahore - Pakistan is the lead sponsor of 27 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-45 years
  • Metabolic syndrome risk (abdominal obesity \& elevated BP as per NCEP ATP III criteria).
  • Low fruit \& veg intake (\<5 serv./day) as per WHO.
  • Willing to follow an intervention
  • Non-pregnant or lactating
  • Not diagnosed with malabsorption syndrome or chronic illness

Exclusion criteria

Exclusion Criteria:

  • Individuals \< 18 years or > 45 years
  • Not at risk of metabolic syndrome.
  • Adequate intake of fruits \& veg (≥ 5 serv./day) as per WHO
  • Not willing
  • Pregnant or lactating
  • Diagnosed with malabsorption syndrome or chronic illness
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Dietary Antioxidant Index-Based Dietary Intervention Arm

    Participants in this arm will receive an antioxidant-rich dietary intervention designed to improve the Dietary Antioxidant Index (DAI). The intervention includes guidance to increase intake of fruits, vegetables, whole grains, legumes, and antioxidant-rich foods while limiting pro-oxidant and ultra-processed foods. Changes in DAI and metabolic syndrome components will be assessed before and after the intervention.

    Other: Antioxidant-Focused Diet Intervention

Interventions

  • OtherAntioxidant-Focused Diet Intervention

    This intervention specifically targets the Dietary Antioxidant Index (DAI) by increasing consumption of antioxidant-rich foods such as fruits, vegetables, whole grains, and legumes, while limiting pro-oxidant and ultra-processed foods. Unlike general healthy diet interventions, this study focuses on quantifiable antioxidant intake and its direct association with metabolic syndrome risk in urban adults.

06

What researchers measure

Primary outcomes

  1. Change in Dietary Antioxidant Index (DAI)

    DAI will be calculated from 24-hour dietary recalls to quantify total antioxidant intake. The primary objective is to assess whether the antioxidant-rich diet increases DAI in participants.

    Time frame: Baseline and after 12 weeks of intervention

  2. Change in Metabolic Syndrome Risk Score

    A composite metabolic syndrome risk score will be calculated by summing standardized z-scores of waist circumference (cm), fasting blood glucose (mg/dL), systolic blood pressure (mmHg), triglycerides (mg/dL), and inversely weighted HDL-cholesterol (mg/dL) to generate a single continuous measure of overall metabolic syndrome risk.

    Time frame: Baseline and after 12 weeks of intervention

Secondary outcomes

  1. Change in Body Composition

    Body composition, including body fat percentage and skeletal muscle mass, will be assessed using InBody analyzer to evaluate changes in body composition.

    Time frame: Baseline and after 12 weeks of intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Apr 2026, 3 months later.

Of 625 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 3 months is below that.

Counting every sponsor, half of 675 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Jan 21, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 15, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07354438
Lead sponsor
University of Veterinary and Animal Sciences, Lahore - Pakistan
Responsible party
Qaisar Raza (Assistant Professor, University of Veterinary and Animal Sciences, Lahore - Pakistan) — Principal investigator
First posted
Jan 21, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Anaum Javed, PG
Contact
anaumjaved768@gmail.com
+92-3040370308
Qaisar Raza, Ph.D
Contact
qaiasr.raza@uvas.edu.pk
+92-3002479044
Qaisar Raza, Ph.D
principal investigator · UNIVERSITY OF VETERINARY & ANIMAL SCIENCES, LAHORE PAKISTAN.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Metabolic Syndrome →

Other studies from this sponsor

University of Veterinary and Animal Sciences, Lahore - Pakistan

Start the discussion